





Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/281,474
Filing Date	March 30, 1999
First Named Inventor	Rajopadhye
Group Art Unit	1619-1616
Examiner Name	D. Jones
Attorney Docket Number	DM-6958

TECH CENTER 1600/2900
OCT 24 2002

+ RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DD	✓	"Cilengitide//Oncolytic Angiogenesis Inhibitor Integrin Alphavbeta3, Alphabeta5 Antagonist" Drugs of the Future, Barcelona, ES, vol 7, no 25, 2000, pp 674-678, XP008002380	
DD	✓	Liu S et al, "90Y and 177LU Labeling of a Dots-Conjugated Vitronection Receptor Antagonist Useful for Tumor Therapy" Bioconjugate Chemistry, American Chemical Society, Washington, US, vol 4, no 12, July 2001, pp 559-568, XP001066363	
DD	✓	Burke P A et al., "Combined Modality Radioimmunotherapy//Promise and Peril" Cancer, American Cancer Society, Philadelphia, PA, US, vol suppl 4, no 94, 15 Feb 2002, pp 1320-1331, XP008001988	

Examiner Signature		Date Considered	1/10/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.